^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Descartes-08

    i
    Other names: Descartes-08, anti-BCMA chimeric antigen receptor T cell therapy, Descartes08, Descartes 08
    Associations

    News

    Trials
    Company:
    Cartesian Therapeutics
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    10d
    SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Cartesian Therapeutics | Recruiting --> Active, not recruiting | N=30 --> 6
    Enrollment closed • Enrollment change
    |
    Descartes-08
    4ms
    Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Cartesian Therapeutics
    New P1/2 trial
    |
    Descartes-08
    6ms
    Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Cartesian Therapeutics | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Jul 2025
    Enrollment closed • Trial primary completion date
    |
    Descartes-08
    8ms
    Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
    P3, N=100, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Descartes-08
    9ms
    Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
    P3, N=100, Not yet recruiting, Cartesian Therapeutics | Trial completion date: Apr 2026 --> Sep 2027 | Trial primary completion date: Apr 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Descartes-08
    10ms
    Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
    P3, N=100, Recruiting, Cartesian Therapeutics
    New P3 trial
    |
    Descartes-08
    over1year
    Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma (clinicaltrials.gov)
    P1, N=32, Terminated, Cartesian Therapeutics | Phase classification: P2 --> P1 | Completed --> Terminated; Phase 1 enrollment completed. Further clinical development terminated
    Phase classification • Trial termination
    |
    cyclophosphamide • fludarabine IV • Descartes-08
    over1year
    Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy (clinicaltrials.gov)
    P2, N=13, Terminated, Cartesian Therapeutics | N=30 --> 13 | Recruiting --> Terminated; Sponsor decision
    Enrollment change • Trial termination
    |
    Descartes-08
    almost2years
    SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=30, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Descartes-08
    almost2years
    SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cartesian Therapeutics | Initiation date: Nov 2023 --> Feb 2024
    Trial initiation date
    |
    Descartes-08
    almost2years
    Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) (clinicaltrials.gov)
    P2, N=30, Recruiting, Cartesian Therapeutics | Trial completion date: Dec 2023 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Mar 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    Descartes-08
    over2years
    Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. (PubMed, Lancet Neurol)
    In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases.
    P1/2 data • Clinical Trial,Phase II • Journal • CAR T-Cell Therapy • IO biomarker
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2)
    |
    Descartes-08